A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Business Unless the context otherwise requires, the terms “we”, “our”, “ours” “us”, “Company” and “Glucotrack” refer to Glucotrack, Inc., a Delaware corporation. The Company was incorporated on May 18, 2010 under the laws of the State of Delaware. We are a medical device company focused on the development of an implantable continuous blood glucose monitor (“CBGM”) for persons with Type 1 diabetes and insulin-dependent Type 2 diabetes (the “Glucotrack CBGM”). The Company was founded with a mission to develop Glucotrack®, a non-invasive glucose monitoring device designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The first generation Glucotrack, which successfully received CE Mark approval, obtained glucose measurements via a small sensor clipped onto one’s earlobe.
| Metric | TTM | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -26M | -2.7M | -3.5M | -40M | -12M | -6.2M |
| EPS | $7,004.49 | $14,820.00 | $-1,560.00 | $-369,720.00 | $-145,860.00 | $-84,240.00 |
| Free Cash Flow | -15M | -3.6M | -3.9M | -4.9M | -5.9M | -5.4M |
| ROIC | -156.8% | -23.3% | 252.7% | -750.6% | 500.6% | -181.6% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 2.29 | 0.02 | -0.13 | -1.24 | -0.00 | -0.00 |
| Dividends/Share | $0.00 | - | - | - | $71.06 | $183.00 |
| Operating Income | -16M | -3.1M | 3.5M | -6.5M | 11M | -5.7M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -939.8% | -30.0% | - | - | - | - |
| Shares Outstanding | 1M | 0M | 0M | 0M | 0M | 0M |
Glucotrack, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
Glucotrack, Inc. trades at 0.0x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Cheap relative to its historical range. At current prices, the estimated annualized return to fair value is +28.9%.
Glucotrack, Inc. (GCTK) has a current P/E ratio of 0.0, compared to its historical median P/E of 15.0. The stock is currently considered Cheap based on its historical valuation range.
Glucotrack, Inc. (GCTK) has a 5-year average return on invested capital (ROIC) of -102.4%. This is below average and may indicate limited pricing power.
Glucotrack, Inc. (GCTK) has a market capitalization of $800K. It is classified as a small-cap stock.
Glucotrack, Inc. (GCTK) does not currently pay a regular dividend.
Based on historical P/E analysis, Glucotrack, Inc. (GCTK) appears cheap. The current P/E of 0.0 is 100% below its historical median of 15.0. The estimated fair value CAGR (P/E method) is 28.9%.
Glucotrack, Inc. (GCTK) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Glucotrack, Inc. (GCTK) generated $-4 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Glucotrack, Inc. (GCTK) has a debt-to-equity ratio of 0.02. This indicates a conservatively financed balance sheet.
Glucotrack, Inc. (GCTK) reported earnings per share (EPS) of $14820.00 in its most recent fiscal year.
Glucotrack, Inc. (GCTK) has a return on equity (ROE) of -30.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 10 years of financial data for Glucotrack, Inc. (GCTK), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Glucotrack, Inc. (GCTK) has a book value per share of $45331.03, based on its most recent annual SEC filing.
No recent press releases.